Tackling Obesity: Approaches, Challenges, and Solutions – Module 2: Pharmacologic Management of Obesity
Released On
November 15, 2025
Expires On
November 14, 2026
Media Type
Internet
Completion Time
15 minutes
Specialty
Primary Care
Topics
Obesity
Acknowledgement
This activity is supported by an independent educational grant from Novo Nordisk.
Credit Available
- Physicians — maximum of 0.25 AMA PRA Category 1 Credit™
- Nurses - 0.25 Nursing Contact Hours
- Nurse Practitioners – 0.25 contact hour(s) of continuing education
- Physician Associates – designated for 0.25 AAPA Category 1 CME Credit
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This education initiative is designed to address the professional needs of NPs and PAs who manage patients with obesity.
Program Overview
This activity focuses on the pharmacologic management of obesity, guiding clinicians through when and how to incorporate obesity management medications into comprehensive care plans for patients. In this brief microlearning module, expert faculty review currently available pharmacologic options, compare efficacy, dosing, and common side effects, and highlight monitoring requirements and contraindications. The content emphasizes shared decision-making and practical strategies for selecting and adjusting therapy in resource limited, rural practices, helping advanced practice providers integrate evidence-based medication management with lifestyle and behavioral interventions to optimize long-term outcomes obesity medications into comprehensive care plans for patients. In this brief microlearning module (0.25 CME), expert faculty review currently available pharmacologic options, compare efficacy, dosing, and common side effects, and making and practical strategies for selecting and adjusting therapy in resource limited, rural practices, helping advanced practice providers integrate evidence based medication management with lifestyle and behavioral interventions to optimize long term outcomes.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Review available pharmacological options for obesity, their efficacy, dosing, and side-effects.
Faculty
Stephanie Rose, MD, MPH
Associate Professor
Internal Medicine and Obesity Medicine
University of Kentucky
Lexington, Kentucky
Caitlin Davidson, DNP, APRN, FNP-C
APP Pharmacy Specialties Supervisor
Department of Internal Medicine
Specialty Pharmacy Infusion Services & General
Internal Medicine
Lexington, Kentucky
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by UK HealthCare CECentral and QDCME. University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
IPCE
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.
CME
This activity is designated for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physician should claim only credit commensurate with the extent of their participation in the activity.
AANP
This activity is approved for 0.25 contact hour(s) of continuing education (which includes 0.75(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 25107559. This activity was planned in accordance with AANP Accreditation Standards and Policies.
AAPA
This activity has been reviewed by the American Academy of Physician Associates Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid from 11/15/2025 to 11/14/2026. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-2014493.
CNE
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 nursing contact hour.
OTHER
UK HealthCare CECentral certifies this activity for 0.25 hours of participation.
Disclosure of Conflicts of Interest
All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.
None of the planners, faculty, and others in control of educational content for this educational activity have relevant financial relationship(s) to disclose with ineligible companies.
The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice.
Speakers will inform the audience when they are discussing investigational and/or off-label uses.
Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be immediately available to the participant.
Disclosures of Unlabeled Use
University of Kentucky College of Medicine requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CME questions please contact: [email protected]